MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
Rhea-AI Summary
MannKind (Nasdaq: MNKD) has announced that it will release its second quarter 2024 financial results on Wednesday, August 7, 2024, before the market opens. The company will issue a press release detailing the quarterly results approximately one hour before hosting a webcast at 9:00 a.m. Eastern Time.
The webcast, accessible to investors, media, and the general public, will feature CEO Michael Castagna and CFO Chris Prentiss. Interested parties can access the webcast through MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will be available in the same location within 24 hours after the call and remain accessible for about 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – MNKD
On the day this news was published, MNKD declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024. A press release detailing the quarterly results will be issued the same day approximately one hour prior to the webcast.
MannKind will host a webcast beginning at 9:00 a.m. Eastern Time for investors, media, and the general public. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
FAQ
When will MannKind (MNKD) report its Q2 2024 financial results?
What time is MannKind's (MNKD) Q2 2024 earnings webcast scheduled for?
Who will be participating in MannKind's (MNKD) Q2 2024 earnings call?
Where can I access MannKind's (MNKD) Q2 2024 earnings webcast?
